Kuros Biosciences announces start of of randomized controlled trial of MagnetOs in spinal fusion

Study should further enhance competitive positioning of MagnetOs Kuros announced that the University Medical Center Utrecht (UMCU) in the Netherlands has obtained approval from its ethical committee to start an investigator-led multicenter study comparing MagnetOs with autologous bone in posterolateral spinal fusion. The study is entitled "A Randomized Controlled Trial of MagnetOs®...

read more

Kuros Biosciences receives European clearance for MagnetOs Putty and prepares for commercial roll-out in the U.S. and Europe

Kuros Biosciences announced today that it has received the CE Mark for MagnetOs Putty indicated for use as an osteoconductive and osteoinductive bone void filler in the skeletal system (i.e. spine, extremities, pelvis, cranium, mandible and maxilla). This market clearance allows commercialization of MagnetOs Putty in Europe, and complements the...

read more